In June, cryptocurrency exchange Crypto.com announced it was laying off around 260 employees, or 5 percent of its workforce, due to the widespread downturn in the crypto market. But layoffs did not end there. Sources in and outside the firm tell The Verge that the company has quietly let go Read more…
TSMC will begin mass producing chips using its leading-edge N3 (3nm-class) manufacturing process this September, according to a Commercial Times report that cites equipment manufacturers. The contract chipmaker will deliver the first products made using its N3 node to its customers early next year. Traditionally, TSMC begins its high-volume manufacturing Read more…
The amount of time US audiences spent watching online TV surpassed cable for the first time ever. Subscribers to services like Netflix and Hulu accounted for 34.8% of all TV consumption in July, the research firm Nielsen said Thursday. That edged out cable TV at 34.4%. Broadcast was a distant Read more…
Quebec’s $303 billion pension manager has written off its stake in bankrupt cryptocurrency lender Celsius Network, with its chief executive officer conceding the fund invested “too soon” in the sector. Charles Emond, CEO of the Caisse de Depot et Placement du Quebec, spoke publicly for the first time Wednesday about Read more…
Blockdata, a crypto research firm, released an updated blog post Tuesday showing who’s been the most active investors in the crypto scene from September 2021 through June 2022. Researchers noted big tech firms including the likes of Tencent, Microsoft, PayPal, Samsung, and Alphabet (Google) are putting big money into crypto Read more…
A Saudi woman has been sentenced to 34 years in prison for retweeting activists through her Twitter account and sharing posts that spoke in favor of the right of women to drive. Salma al-Shehab was a PhD candidate at the University of Leeds in the UK and was detained in Read more…
The U.S. Food and Drug Administration on Wednesday approved bluebird bio’s gene therapy for patients with a rare disorder requiring regular blood transfusions, and the drugmaker priced it at a record $2.8 million. The approval sent the company’s shares 8% higher and is for the treatment of beta-thalassemia, which causes Read more…